Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2016.

Medical device companies raised a total of $906 million in Q3, while in vitro diagnostic/research developers took in $72 million. The top M&As in each segment were private buyouts of public companies: Kinetic Concepts for $6.3 billion and Immucor for $1.9 billion.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research/analytical instrumentation and reagent sectors.